Revolution Medicines (RVMD)
(Delayed Data from NSDQ)
$55.87 USD
+0.78 (1.42%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $55.87 0.00 (0.00%) 4:36 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RVMD 55.87 +0.78(1.42%)
Will RVMD be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for RVMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RVMD
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
RVMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates
Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?
Other News for RVMD
Promising Clinical Trial Results and Strategic Combination Bolster Buy Rating for Revolution Medicines
Revolution Medicines price target raised to $62 from $56 at H.C. Wainwright
Revolution Medicines price target raised by $6 at H.C. Wainwright, here's why
TD Cowen Reaffirms Their Buy Rating on Revolution Medicines (RVMD)
Revolution Medicines (RVMD) Gets a Buy from Barclays